Premium
Vascular endothelial growth factor sustained delivery augmented cell therapy outcomes of cardiac progenitor cells for myocardial infarction
Author(s) -
Montazeri Leila,
Sobat Motahareh,
KowsariEsfahan Reza,
Rabbani Shahram,
Ansari Hassan,
Barekat Maryam,
Firoozi Saman,
Rajabi Sarah,
Vahdat Sadaf,
Baharvand Hossein,
Pahlavan Sara
Publication year - 2020
Publication title -
journal of tissue engineering and regenerative medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.835
H-Index - 72
eISSN - 1932-7005
pISSN - 1932-6254
DOI - 10.1002/term.3125
Subject(s) - transplantation , myocardial infarction , progenitor cell , medicine , vascular endothelial growth factor , cardiology , embryonic stem cell , cell therapy , endothelial stem cell , cancer research , stem cell , microbiology and biotechnology , chemistry , biology , vegf receptors , in vitro , biochemistry , gene
Cell therapy has become a novel promising approach for improvement of cardiac functional capacity in the instances of ventricular remodeling and fibrosis caused by episodes of coronary artery occlusion and hypoxia. The challenge toward enhancing cell engraftment as well as formation of functional tissue, however, necessitated combinatorial approaches. Here, we complemented human embryonic stem cell‐derived cardiac progenitor cell (hESC‐CPC) therapy by heparin‐conjugated, vascular endothelial growth factor (VEGF)‐loaded fibrin hydrogel as VEGF delivery system. Transplantation of these cardiac committed cells along with sustained VEGF release could surpass the cardiac repair effects of each constituent alone in a rat model of acute myocardial infarction. The histological sections of rat hearts revealed improved vascularization as well as inclusion of hESC‐CPC‐derived cardiomyocytes, endothelial, and smooth muscle cells in host myocardium. Thus, co‐transplantation of hESC‐CPC and proangiogenic factor by a suitable delivery rate may resolve the shortcomings of conventional cell therapy.